Assetmark Inc. Has $6.89 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Assetmark Inc. boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 11.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 62,802 shares of the medical equipment provider’s stock after purchasing an additional 6,442 shares during the quarter. Assetmark Inc.’s holdings in Lantheus were worth $6,893,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in LNTH. Signaturefd LLC boosted its position in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the last quarter. GAMMA Investing LLC lifted its stake in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares during the period. UMB Bank n.a. boosted its holdings in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus during the 3rd quarter worth about $51,000. Finally, Nkcfo LLC bought a new stake in shares of Lantheus in the 2nd quarter valued at about $47,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

NASDAQ LNTH opened at $84.08 on Tuesday. The stock has a market capitalization of $5.85 billion, a price-to-earnings ratio of 13.99 and a beta of 0.51. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The stock’s 50 day moving average price is $106.89 and its two-hundred day moving average price is $96.26.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Truist Financial reissued a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday. B. Riley upped their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic began coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. JMP Securities lowered their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Finally, StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Friday. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.